Isomorphic Labs and Merck, known as MSD outside the United States and Canada, have agreed to collaborate on therapeutic small-molecule candidates against an oncology target that neither company has named. The announcements came on 19 November 2026, in a Merck release and a same-day post from Isomorphic Labs.
The target, the value of the deal and any timelines were not disclosed. No candidates or results were published with the news.
Under the agreement, Isomorphic Labs “will perform in silico predictions and deliver molecular designs, applying its proprietary drug design engine (IsoDDE) incorporating select high-quality proprietary data sets supplied by Merck for the purpose of this collaboration.” Merck “will be responsible for preclinical and clinical development, as well as manufacturing and commercialization of any products derived from the collaboration.” That last phrase is conditional. There is no product yet.
The commercial terms are described, not priced. Isomorphic “will receive an upfront payment from Merck and be eligible for payments based on the achievement of specified research, development, regulatory and commercial milestones, as well as tiered royalties on net sales.” It also “receives an option to co-fund development activities in return for elevated royalties.” Neither announcement states the size of the upfront payment, the milestones or the royalty rates.
Merck’s release describes Isomorphic as an “AI-first drug design and development company” and says it has built IsoDDE as a “modality-agnostic drug design engine (IsoDDE) comprised of foundational AI models.” The same about section says the firm was founded in 2021, is led by chief executive Sir Demis Hassabis and president Max Jaderberg, and “is advancing a broad and ambitious drug design portfolio through partnered programs and wholly owned internal programs.” This Merck agreement is one of those partnered programmes. It does not, on this record, add a named molecule to the portfolio or say which internal programmes, if any, sit alongside it.
The split of labour is the part of the story that can be reported with confidence. The London-based company, whose headquarters Merck’s release records in London, with offices in Cambridge, Massachusetts and Lausanne, will do the computational design. Merck will take anything that comes out of that work through the laboratory, the clinic and, if it ever gets that far, the market. George Addona, senior vice president and head of discovery, preclinical development and translational medicine at Merck Research Laboratories, put the ambition in those terms: “The key to successfully leveraging AI/ML for molecular invention lies in close coordination of wet-lab and dry-lab functions.” The companies, he said, “aim to identify new ways to design and create better candidates faster.” That is an aim, not a result already in hand.
Sarah Skerratt, Isomorphic’s chief research officer, said that “by leveraging the generative and predictive power of the IsoDDE to address this challenging program, this collaboration highlights our companies’ shared commitment to innovation for the benefit of patient populations with unmet needs.” Claims in the same materials that the firm’s engine is “world-leading” or offers “unprecedented accuracy” are the companies’ wording. They are not independently demonstrated in these announcements.
The collaboration lands two days after Isomorphic announced a $5 billion Series C to scale IsoDDE and move candidates towards clinical trials. That round, which the company did not value, is a funding event. This week’s Merck agreement is a research collaboration on a single, unnamed oncology target. They should not be read as the same news, and the new deal does not fill in the missing valuation or the missing price. TSN earlier covered reported talks around Isomorphic’s fundraising; those talks are not a substitute for the terms left blank here.
Other AI molecular-design firms are also signing drugmakers. Boltz, which began as an MIT project, said this week it had raised a $110 million Series A and claimed partnerships with large pharmaceutical companies. That is a different company and a different kind of announcement. It does not tell readers what Merck and Isomorphic will pay, which tumour biology they have chosen, or when a molecule might enter a lab.
A research collaboration is not a candidate, and an upfront payment is not a published price
The useful facts are narrow, and they should stay narrow. Two official texts agree that Isomorphic will design small molecules, using IsoDDE and selected Merck data, against one oncology target of “strategic importance,” and that Merck will run development and commercialisation if anything usable appears. The money is real in structure: an upfront payment, milestones, tiered royalties and a co-funding option. The amounts are not.
What the announcements do not do is name the target, date a first experiment, or show a molecule that has already been made and tested. Addona’s “better candidates faster” is a goal. Skerratt’s patient-benefit line is a hope. Until a target, a figure or a laboratory result is published, the accurate reading is the one in the two releases: a London AI drug-design company and Merck have started an unpriced oncology collaboration, with computational design on one side and development responsibility on the other. The next facts to watch are a named target, a disclosed payment, or the first sign that a design has left the computer.
Sources
- Merck, “Merck and Isomorphic Labs Enter Strategic Research Collaboration,” 19 November 2026.
- Isomorphic Labs, “Isomorphic Labs enters into a strategic research collaboration with MSD,” 19 November 2026.
Get TSN’s biggest tech stories, explained.
News and insights across AI, tech, crypto and cybersecurity. Every source linked. Unsubscribe anytime.
Get the newsletterRelated stories
Isomorphic Labs Announces a $5 Billion Series C Funding Round is the closest recent TSN account of the same company’s drug-design engine, announced two days earlier, and is the next read.
- Boltz Raises $110 Million Series A for Molecular Design Tools
- Firmus Pulls Its ASX IPO as Isomorphic Labs Eyes a $40bn Valuation
Follow @tsnmediahub on X for breaking AI news as it happens.
Follow on X

